New Antibody Advances 2021 International Clinical Webinar
The One Lambda™ LABScreen™ product portfolio continues to improve advances in HLA antibody detection by our continued research to develop more stable HLA class II antigens, reducing potential denatured reactions in HLA antibody tests due to pan DR activity. Learn how the LABScreen ReFlex platform removes pan-DR reactivity, resolves discordant class II reactivity, and reveals true specificity for HLA class II antigens. Also learn about PreSorb, which removes an autoreactive antibody in serum that recognizes an antigenic determinant for all DR alleles as well as Cw1, Cw12, and Cw15 epitopes.
Speakers:
Dave Lowe, PhD, FRC Path
Senior Research and Development Director, Thermo Fisher Scientific
West Hills, CA USA
Recorded:
Oct 20, 2021
Videos In This Series
- New Antibody Advances ❯
- The Potential of Imlifidase ❯
- Advancements in AllType FASTPlex ❯
- An Introduction to and the Evolution of the UK Living Kidney Sharing Scheme ❯
- HLA Typing by Next-Generation Sequencing (NGS) Using the AllType Fastplex Kit and the Relevance of Anti-HLA Antibody Monitoring After Kidney Transplantation ❯
- Non-HLA Antibodies: Preliminary Experience ❯
© 2025 Thermo Fisher Scientific Inc. All rights reserved.